Drug Type Small molecule drug |
Synonyms LP, Simmitecan hydrochloride |
Target |
Action inhibitors |
Mechanism TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC34H39ClN4O6 |
InChIKeyUWNITDCAZZJJFF-GXUZKUJRSA-N |
CAS Registry1247847-78-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuroendocrine Tumors | Phase 3 | China | - | |
Colorectal Cancer | Phase 2 | China | 26 Feb 2019 | |
Colorectal Cancer | Phase 2 | China | 26 Feb 2019 | |
Metastatic Colorectal Carcinoma | Phase 1 | China | 01 Oct 2016 | |
Rectal Cancer | Phase 1 | China | 01 Oct 2016 | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 01 Dec 2012 | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 01 Dec 2012 |
Phase 1 | 41 | qywgdscdlg(vogwhxayye) = similar, i.e. anemia and febrile neutropenia (11.1% each) in LP, diarrhea (10%) in LP+5-FU/LV, febrile neutropenia (5.6%) in LP+T. hmqhtmkzoa (lijenupsdy ) | Positive | 29 May 2020 | |||
5-fluorouracil+leucovorin+simmitecan |